CERE News and Press, Ceres Inc. From 12/04/20

CAMBRIDGE, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced it will host a live webcast providing a current corporate overview, followed by ...

BOSTON, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced Chairperson and Chief Executive Officer Tony Coles, M.D., will participate in a fireside c...

The following slide deck was published by Cerevel Therapeutics Holdings, Inc. in conjunction with this event. For further details see: Cerevel Therapeutics (CERE) Investor Presentation - Slideshow

Cerevel Therapeutics (CERE): Q3 GAAP EPS of -$7.73.Cash and cash equivalents at the end of quarter was $13M.Press Release For further details see: Cerevel Therapeutics reports Q3 results

Participants dosed in clinical trials for lead programs in schizophrenia, epilepsy, anxiety and Parkinson’s disease Debuted as publicly traded entity under symbol CERE Net proceeds of approximately $440 million raised from completed business combination transa...

BOSTON, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in three upcoming virtual investor con...

The first participants have been dosed in Cerevel Therapeutics' (CERE) all three of the clinical trials in their Phase 3 program evaluating tavapadon in patients with Parkinson’s disease. The Phase 3 program includes three 27-week, placebo-controlled, parallel-group trials designed to ...

BOSTON, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that the first participants have been dosed in all three of the clinical trials in th...

B usiness combination transaction with Arya Sciences Acquisition Corp II, a special purpose acquisition company sponsored by Perceptive Advisors, completed on October 27, 2020 Combined company renamed Cerevel Therapeutics Holdings , Inc. ...